Kewaunee Scientific Corp Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.82 Intrinsic Value $32.36median of 6 methods · middle span $30-$63based on filings through 31 Jul 2026 Market Price $33.91Price as of 1 Oct 2026 Near fair valueIntrinsic value is 5% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $98.2M Enterprise Value $108.8M Shares Outstanding 2.9M diluted Moat Rating Wide Last ex-dividend9 Sep 2019 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Kewaunee Scientific Corporation (KEQU) is a global leader in laboratory, healthcare, and technical furniture. The company's strategic acquisition of Nu Aire, Inc. in late 2024 has significantly expanded its product portfolio into biological safety cabinets and laboratory equipment, driving strong top-line growth. However, near-term earnings are pressured by integration costs, compliance expenses (such as Sarbanes-Oxley 404(b)), and volatility in project delivery timelines. While the long-term outlook remains positive due to a robust backlog and international expansion (particularly in India), uneven quarterly performance and project delivery delays warrant a Hold recommendation until integration synergies fully materialize and earnings stabilize. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $32.0020% Integration challenges with Nu Aire lead to customer attrition and margin dilution. Broader economic slowdown or government policy uncertainty delays capital expenditure budgets for laboratory construction, leading to a significant decline in the order backlog and lower manufacturing volumes. Base CaseCentral scenario $40.0050% Nu Aire integration proceeds steadily, supporting mid-single-digit organic growth. Volatility in project delivery timelines persists, causing uneven quarterly results. Corporate platform investments continue to weigh on near-term margins, but EBITDA improves year-over-year. Bull CaseUpside scenario $48.0030% Rapid integration of Nu Aire leads to higher-than-expected cost synergies and cross-selling opportunities, driving gross margins above 30%. International markets, particularly India, experience accelerated laboratory construction, clearing the backlog faster and boosting high-margin international segment earnings. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |